Tri-Lo-Mili

Prescription Required
Generic
Dose Size & Price Qty
0.180/0.035/0.215/0.035/0.250/0.035mg
  • Description
  • Reviews (0)
  • Related Products
  • Related Conditions

This combination hormone medication is used to prevent pregnancy. It contains 2 hormones: a progestin and an estrogen. It works mainly by preventing the release of an egg (ovulation) during your menstrual cycle. Tri-Lo-Mili is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime, (17a)-(+)-) and ethinyl estradiol is designated as (19-nor-17a-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Each active white to off white tablet contains 0.180 mg of norgestimate USP and 0.025 mg of ethinyl estradiol USP. Inactive ingredients include croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide. Each active pale blue to bluish white tablet contains 0.215 mg of norgestimate USP and 0.025 mg of ethinyl estradiol USP. Inactive ingredients include croscarmellose sodium, FD&C Blue #2/Indigo carmine aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide. Each active blue to light blue tablet contains 0.250 mg of norgestimate USP and 0.025 mg of ethinyl estradiol USP. Inactive ingredients include croscarmellose sodium, FD&C Blue #2/Indigo carmine aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide. Each green placebo tablet contains only inert ingredients, as follows: anhydrous lactose, FD&C Blue No. 2 aluminum lake, ferric oxide yellow, magnesium stearate, microcrystalline

Ingredients

0.180 mg/0.025 mg, 0.215/0.025 mg, & 0.250/0.025 mg (norgestimate and ethinyl estradiol tablets USP)

Cautions

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see CONTRAINDICATIONS (4)].

Side Effects

•Body fluid retention •Mastalgia •Acne vulgaris •Dizziness •Nausea •Vomiting •Abdominal distension •Headache disorder

No Reviews